The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Oralair 300 IR
ANTHOXANTHUM ODORATUM POLLEN, DACTYLIS GLOMERATA POLLEN, LOLIUM PERENNE POLLEN, PHLEUM PRATENSE POLLEN, and POA PRATENSIS POLLEN · DACTYLIS GLOMERATA POLLEN 300 [IR]/1; ANTHOXANTHUM ODORATUM POLLEN 300 [IR]/1; LOLIUM PERENNE POLLEN 300 [IR]/1; PHLEUM PRATENSE POLLEN 300 [IR]/1; POA PRATENSIS POLLEN 300 [IR]/1 · Tablet, Orally Disintegrating · Sublingual · Cenexi Hsc
NDC 82454-0015-02 · 30 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK · BLA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 59617-0015-02) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$15.23per unit
middle half $14.69–$15.30 · 314 plans · Jul 1, 2024
Est. net of rebatesⓘ
$9.14–$11.42
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
—of plans cover it
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 3 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA125471
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of ANTHOXANTHUM ODORATUM POLLEN, DACTYLIS GLOMERATA POLLEN, LOLIUM PERENNE POLLEN, PHLEUM PRATENSE POLLEN, and POA PRATENSIS POLLEN (Tablet, Orally Disintegrating)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Cenexi Hsc | DACTYLIS GLOMERATA POLLEN 300 [IR]/1; ANTHOXANTHUM ODORATUM POLLEN 300 [IR]/1; LOLIUM PERENNE POLLEN 300 [IR]/1; PHLEUM PRATENSE POLLEN 300 [IR]/1; POA PRATENSIS POLLEN 300 [IR]/1 | Jul 22, 2026 | Sep 2, 2026 |
| Stallergenes | DACTYLIS GLOMERATA POLLEN 300 [IR]/1; ANTHOXANTHUM ODORATUM POLLEN 300 [IR]/1; LOLIUM PERENNE POLLEN 300 [IR]/1; PHLEUM PRATENSE POLLEN 300 [IR]/1; POA PRATENSIS POLLEN 300 [IR]/1 | Jul 22, 2026 | Sep 2, 2026 |
| Stallergenes | POA PRATENSIS POLLEN 100 [IR]/1; DACTYLIS GLOMERATA POLLEN 100 [IR]/1; ANTHOXANTHUM ODORATUM POLLEN 100 [IR]/1; LOLIUM PERENNE POLLEN 100 [IR]/1; PHLEUM PRATENSE POLLEN 100 [IR]/1 | Jul 22, 2026 | Sep 2, 2026 |
| Stallergenes | POA PRATENSIS POLLEN 300 [IR]/1; DACTYLIS GLOMERATA POLLEN 300 [IR]/1; ANTHOXANTHUM ODORATUM POLLEN 300 [IR]/1; LOLIUM PERENNE POLLEN 300 [IR]/1; PHLEUM PRATENSE POLLEN 300 [IR]/1 | Jul 22, 2026 | Sep 2, 2026 |
| Stallergenes | ANTHOXANTHUM ODORATUM POLLEN 300 [IR]/1; DACTYLIS GLOMERATA POLLEN 300 [IR]/1; LOLIUM PERENNE POLLEN 300 [IR]/1; PHLEUM PRATENSE POLLEN 300 [IR]/1; POA PRATENSIS POLLEN 300 [IR]/1 | Jul 15, 2026 | Jul 19, 2026 |
| Cenexi Hsc | ANTHOXANTHUM ODORATUM POLLEN 300 [IR]/1; DACTYLIS GLOMERATA POLLEN 300 [IR]/1; LOLIUM PERENNE POLLEN 300 [IR]/1; PHLEUM PRATENSE POLLEN 300 [IR]/1; POA PRATENSIS POLLEN 300 [IR]/1 | Jul 15, 2026 | Jul 15, 2026 |
| Stallergenes | ANTHOXANTHUM ODORATUM POLLEN 100 [IR]/1; DACTYLIS GLOMERATA POLLEN 100 [IR]/1; LOLIUM PERENNE POLLEN 100 [IR]/1; PHLEUM PRATENSE POLLEN 100 [IR]/1; POA PRATENSIS POLLEN 100 [IR]/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Oralair 300 IR — NDC 82454-0015-02," retrieved September 3, 2026, https://drugdashboards.com/drug/82454001502.
Free to cite with attribution — see how the data is put together.